Primary stent implantation for acute myocardial infarction during pregnancy: use of abciximab, ticlopidine, and aspirin.
Recent evidence suggests that coronary stenting and the use of antiplatelet agents during coronary interventions will improve the outcome of patients with acute myocardial infarction (AMI). We describe the management of AMI in a 30-year-old woman, 38 weeks pregnant, with primary stenting and antiplatelet agents.
Sebastian
C
C
Taranaki Base Hospital, New Plymouth, New Zealand.
Scherlag
M
M
Kugelmass
A
A
Schechter
E
E
D000077284:Abciximab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D019917:Blood Vessel Prosthesis Implantation; D017023:Coronary Angiography; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007231:Infant, Newborn; D008297:Male; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular; D015607:Stents; D013988:Ticlopidine / Q000008:administration & dosage / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin; D000077284:Abciximab